The complete reference for growth hormone-releasing hormone analogues — sermorelin, CJC-1295, and tesamorelin. Mechanism, half-life comparison, FDA status and the human evidence. Research use only; we do not publish dosing.
Growth hormone-releasing hormone (GHRH) is a 44-amino acid peptide produced by the hypothalamus that stimulates the anterior pituitary to synthesize and secrete growth hormone (GH). It is the primary upstream regulator of the GH/IGF-1 axis, acting in concert with somatostatin (which inhibits GH release) to produce the characteristic pulsatile GH secretion pattern observed in healthy individuals.
GHRH analogues are synthetic peptides designed to mimic or improve upon endogenous GHRH. The key engineering challenge is extending the extremely short half-life of native GHRH (~7 minutes in plasma) while preserving receptor selectivity. Each approved or investigational analogue takes a different structural approach to this problem, resulting in meaningfully different pharmacokinetic profiles and clinical applications.
All GHRH analogues bind the GHRH receptor (GHRHR) on somatotroph cells in the anterior pituitary. This G-protein coupled receptor activates adenylyl cyclase, increasing intracellular cAMP.
Elevated cAMP activates protein kinase A (PKA), which phosphorylates transcription factors including Pit-1, stimulating GH gene transcription and triggering exocytosis of stored GH granules.
Released GH travels to the liver and peripheral tissues, stimulating IGF-1 production. IGF-1 mediates most of GH's anabolic effects — muscle protein synthesis, lipolysis, and bone mineralization.
Unlike exogenous HGH, GHRH analogues preserve the somatostatin-mediated negative feedback loop. This prevents supraphysiological GH levels and maintains pituitary sensitivity over time.
| Parameter | Sermorelin | CJC-1295 | Tesamorelin |
|---|---|---|---|
| Structure | GHRH(1-29) | GHRH(1-29) + DAC modification | GHRH(1-44) + N-terminal hexenoic acid |
| Half-life | ~11 minutes | ~8 days (with DAC) | ~26 minutes |
| GH release pattern | Pulsatile (physiological) | Sustained blunted pulse | Pulsatile (stronger than sermorelin) |
| FDA approval | Withdrawn 2008 (was approved for children) | None | Yes (2010, HIV-associated abdominal fat) |
| Human evidence | Paediatric GH deficiency (historic) | Early PK studies; development stopped | Phase 3 trials in HIV lipodystrophy |
| Established dose | Only on the withdrawn label | None | Set by the Egrifta label, for its approved use |
Two GHRH analogues act on the same receptor, so pairing them adds nothing in principle. Pairing a GHRH analogue with a growth hormone-releasing peptide (GHRP) such as ipamorelin is different: the GHRP acts on the ghrelin receptor (GHS-R1a), and in studies of GHRH and GHRP given together the GH response was larger than with either alone.
That is the whole evidence base for the "stacks" sold online. No trial has tested sermorelin, CJC-1295 or tesamorelin combined with ipamorelin for fat loss, muscle, sleep or ageing, and no dose or schedule for any combination has been established. Compound Review does not publish dosing or stack protocols. Outside tesamorelin's approved use, these compounds are sold for laboratory research only and are not for human or animal consumption.
A GHRH analogue is a synthetic peptide that mimics growth hormone-releasing hormone (GHRH), the hypothalamic peptide that stimulates the pituitary to produce and release growth hormone. Unlike exogenous HGH, GHRH analogues work upstream — they stimulate the body's own GH production rather than replacing it.
GHRH analogues (sermorelin, CJC-1295, tesamorelin) bind the GHRH receptor and stimulate GH synthesis and release via the cAMP pathway. GHRPs (growth hormone-releasing peptides) such as ipamorelin and GHRP-6 bind the ghrelin receptor (GHS-R1a) and amplify GH release via a different pathway. In studies, giving one of each produced larger GH responses than either alone; no combination has been trialled for a health outcome.
Tesamorelin is the only one with trial evidence: in Phase 3 trials in people with HIV-associated abdominal fat, visceral fat fell by roughly 15% over 26 weeks versus placebo, which led to its FDA approval for that use alone. CJC-1295 and sermorelin have no fat-loss trials, and none of these has been shown to reduce fat in people without HIV lipodystrophy.
None has evidence for either. Sermorelin is often marketed for ageing and sleep because it produces pulsatile GH release, but no controlled trial has shown an anti-ageing or sleep benefit in healthy adults, and its US approval (for children with GH deficiency) was withdrawn in 2008.
Two GHRH analogues share a receptor, so combining them adds nothing in principle. GHRH plus GHRP pairs gave larger GH responses in studies, but no combination has been trialled for any outcome, and we do not publish stack or dosing protocols.
Purgo Labs provides pharmaceutical-grade GHRH analogue peptides with third-party COA verification, ≥99% purity, and cGMP manufacturing standards. Use code HEALTH for 20% off.
Shop Purgo Labs